Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.72 |
| ▸ | TNKS | O95271 | 2/20 | 0.64 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124101 | 0.84 | TNKS2 (0.80) | TNKS2TNKSPARP3ALDH1A1KMT2A | |
| SCHEMBL6124107 | 0.84 | TNKS2 (0.80) | TNKS2TNKSPARP3ALDH1A1KMT2A | |
| SCHEMBL29913643 | 0.84 | TNKS2 (1.00) | TNKS2TNKSPARP3ALDH1A1KMT2A | |
| SCHEMBL6124214 | 0.84 | TNKS2 (0.80) | TNKS2TNKSPARP3ALDH1A1KMT2A | |
| SCHEMBL6124233 | 0.81 | TNKS2 (0.49) | TNKS2TNKSPARP3ALDH1A1KMT2A | |
| SCHEMBL5248973 | 0.80 | TNKS2 (1.00) | TNKS2TNKSPARP3ALDH1A1KMT2A | |
| SCHEMBL29913499 | 0.80 | TNKS2 (1.00) | TNKS2TNKSPARP3ALDH1A1KMT2A | |
| SCHEMBL29265402 | 0.80 | TNKS2 (0.91) | TNKS2TNKSPARP3ALDH1A1KMT2A | |
| SCHEMBL28853485 | 0.78 | TNKS2 (1.00) | TNKS2TNKSPARP3ALDH1A1KMT2A | |
| SCHEMBL24743516 | 0.78 | TNKS2 (1.00) | TNKS2TNKSPARP3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1750706-B1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | Univ Virginia Patent Found (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8298512-B2 | Methods of determining β-III tubulin expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8298512-B2 | Methods of determining β-III tubulin expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-8178545-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178545-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-18 | — | — | US | disclosed |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-18 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | TNKS2 476/4885TNKS 981/4885PARP3 696/4885 |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | TUBB3, TUBB1, TUBB | TNKS2 1338/4885TNKS 2351/4885PARP3 264/4885 |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | TNKS2 476/4885TNKS 981/4885PARP3 696/4885 |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | TP53, MAP2, MAP1LC3B | TNKS2 476/4885TNKS 981/4885PARP3 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.